Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.

Abstract:

BACKGROUND:Cisplatin (CDDP) ototoxicity is a significant side effect of the current treatment of medulloblastoma (MB). Cumulative dose of CDDP and age are recognized risk factors for hearing loss, but inter-individual susceptibility limits our ability to identify patients at risk for hearing loss. We describe the kinetics of early audiometric changes during therapy and identify profiles associated with a higher risk of needing hearing aids. PROCEDURE:Serial audiometric evaluations were performed during and after completion of therapy in children with average risk (AR) and high-risk (HR) MB. Each audiogram was scored according to five grading systems. Variations of pure tone thresholds were analyzed at each frequency for each consecutive audiogram. CDDP dose modifications and hearing outcome were recorded. RESULTS:A total of 258 audiograms from 35 patients (22 AR, 13 HR) were analyzed. Eighteen AR patients (81.3%) required dose reduction and the median cumulative dose of CDDP administered was 412.5 mg/m(2) (150-600), corresponding to 68% of the intended dose. Three HR patients (23.0%) required dose reduction. At a median follow-up of 67 months (11-117), nine patients (25.7%) required hearing support: After two cycles of CDDP (150 mg/m(2) ), the average hearing loss at 8,000 Hz was twice higher in the group that eventually required hearing support. CONCLUSION:Early alteration of high-frequency thresholds may help identify individuals who will require hearing support. In the MB population, alternative strategies should be developed to limit the cumulative dose of CDDP to prevent significant ototoxicity.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Lafay-Cousin L,Purdy E,Huang A,Cushing SL,Papaioannou V,Nettel-Aguirre A,Bouffet E

doi

10.1002/pbc.24307

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

287-92

issue

2

eissn

1545-5009

issn

1545-5017

journal_volume

60

pub_type

杂志文章
  • Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country.

    abstract:BACKGROUND:An adapted LMB 96 derived protocol for B-cell non-Hodgkin lymphoma (NHL) was implemented at the pediatric oncology unit of the Children Welfare Teaching Hospital in Baghdad (Iraq) from 2000 to present. The purpose was to evaluate the feasibility and efficacy of this intensive therapeutic regimen in a limited...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22905

    authors: Moleti ML,Al-Hadad SA,Al-Jadiry MF,Al-Darraji AF,Al-Saeed RM,De Vellis A,Piciocchi A,Uccini S,Foà R,Testi AM

    更新日期:2011-04-01 00:00:00

  • In-hospital mortality of hematopoietic stem cell transplantation among children with nonmalignancies: A nationwide study in the United States from 2000 to 2012.

    abstract:BACKGROUND:Hematopoietic stem cell transplant (HSCT) can cure or alleviate a wide range of nonmalignant childhood conditions. However, few studies have examined longitudinal national trends of frequency or short-term complications of HSCT before 2006 when an HSCT became a reportable procedure by US law. By using a US n...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27626

    authors: Takahashi T,Pereda MA,Bala N,Nagarajan S

    更新日期:2019-06-01 00:00:00

  • Efficacy and toxicity of plerixafor for peripheral blood stem cell mobilization in children with high-risk neuroblastoma.

    abstract::Six patients with high-risk neuroblastoma underwent the second stem cell collection round with G-CSF (5 μg/kg/day) + plerixafor (0.24 mg/kg/day) because the amount of CD34(+) cells collected during the first collection round with G-CSF alone was insufficient. The number of CD34(+) cells collected in the second collect...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24506

    authors: Son MH,Kang ES,Kim DH,Lee SH,Yoo KH,Sung KW,Koo HH,Kim DW,Kim JY,Cho EJ

    更新日期:2013-08-01 00:00:00

  • Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients.

    abstract:BACKGROUND:Little is known about the effects of chemotherapy on patient antibody titers to vaccine-preventable infectious diseases; thus, there is no standard protocol for revaccinating post-chemotherapy patients. PROCEDURES:To assess losses of detectable antibody titers due to chemotherapy, we retrospectively examine...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21277

    authors: Yu J,Chou AJ,Lennox A,Kleiman P,Wexler LH,Meyers PA,Gorlick R

    更新日期:2007-10-15 00:00:00

  • Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax.

    abstract:BACKGROUND:Ewing sarcoma of the thoracic spine and chest wall is frequently treated with concurrent chemotherapy and radiation therapy (RT). Treatment-related acute esophagitis can lead to hospitalization and treatment delays. The aim of this study was to analyze the incidence, risk factors, and management of esophagit...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.27006

    authors: Agarwal V,Logie N,Morris CG,Bradley JA,Rotondo RL,Bradfield SM,Indelicato DJ

    更新日期:2018-06-01 00:00:00

  • Patient-reported health status during pediatric cancer treatment.

    abstract:BACKGROUND:Changes in patient function and factors affecting pediatric patients with cancer during treatment are largely unknown. The purpose of this study was to measure patient-reported outcomes (PROs) in children during the initial 6 months of therapy to characterize function and explore factors associated with func...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26295

    authors: Dobrozsi S,Yan K,Hoffmann R,Panepinto J

    更新日期:2017-04-01 00:00:00

  • Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma.

    abstract:BACKGROUND:Over the past decade, PET-CT has been used to assess rhabdomyosarcoma (RMS) in children. However, the role of PET-CT in staging RMS is unknown. PROCEDURE:Thirty subjects with RMS, median age 7.3 years, underwent PET-CT before therapy. PET-CTs and conventional imaging (CI) were independently reviewed by two ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24430

    authors: Federico SM,Spunt SL,Krasin MJ,Billup CA,Wu J,Shulkin B,Mandell G,McCarville MB

    更新日期:2013-07-01 00:00:00

  • Reduced-toxicity alternate-donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders.

    abstract::We describe here the outcomes of reduced-toxicity alternate-donor stem cell transplant (SCT) with posttransplant cyclophosphamide (PTCy) for primary immunodeficiency disorders (PIDs) in eight children (haploidentical-seven and matched unrelated donor-one). The conditioning was with serotherapy (alemtuzumab-3/rabbit-an...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26783

    authors: Rastogi N,Katewa S,Thakkar D,Kohli S,Nivargi S,Yadav SP

    更新日期:2018-01-01 00:00:00

  • Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain.

    abstract:BACKGROUND:Pain is the most common complication of sickle cell disease requiring emergency department (ED) visits and hospitalization. A Clinical Practice Guideline (CPG) to manage acute sickle cell pain offers clinicians a standardized approach for the provision of evidence-based, cost-effective care. After CPG implem...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21847

    authors: Morrissey LK,Shea JO,Kalish LA,Weiner DL,Branowicki P,Heeney MM

    更新日期:2009-03-01 00:00:00

  • Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience.

    abstract:BACKGROUND:Nephrogenic rests (NRs) are abnormally persistent foci of embryonal cells, thought to be the precursor lesion of Wilms tumors (WTs). To date, their presence has not been systematically examined in WTs treated with preoperative chemotherapy. METHODS:A systematic analysis of the data on NRs in WTs treated wit...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.26547

    authors: Vujanić GM,Apps JR,Moroz V,Ceroni F,Williams RD,Sebire NJ,Pritchard-Jones K

    更新日期:2017-11-01 00:00:00

  • Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies.

    abstract::Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics. This myleoproliferative disorder is characterized by excessive proliferation of megakaryocytes and sustained elevation of platelet count. Reactive thrombocytosis is a more common cause of elevated platelet counts among children. We describe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21218

    authors: Robins EB,Niazi M

    更新日期:2008-04-01 00:00:00

  • Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.

    abstract:PURPOSE:To determine the safety, efficacy, and PK profile of intravenous busulfan (Bu) in the context of a Bu and cyclophosphamide (IVBuCy) preparative regimen in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS:Twenty-four children were enrolled in an open-label, multicenter tria...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/pbc.22227

    authors: Wall DA,Chan KW,Nieder ML,Hayashi RJ,Yeager AM,Kadota R,Przepiorka D,Mezzi K,Kletzel M,Pediatric Blood, Marrow Transplant Consortium.

    更新日期:2010-02-01 00:00:00

  • Pilomyxoid astrocytoma treated successfully with vemurafenib.

    abstract::The BRAF V600E missense mutation is known to be present in a subset of central nervous system tumors. We report a patient with a BRAF V600E mutated pilomyxoid astrocytoma who failed multiple conventional chemotherapy regimens. Treatment with vemurafenib, a molecularly targeted therapy against the mutant BRAF V600E kin...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25084

    authors: Skrypek M,Foreman N,Guillaume D,Moertel C

    更新日期:2014-11-01 00:00:00

  • Mortality in children with low-grade glioma or glioneuronal tumors: A single-institution study.

    abstract:BACKGROUND:While pediatric low-grade glioma/glioneuronal tumors (LGG/LGGNTs) are considered slow-growing, indolent tumors with excellent long-term prognosis, mortality due to the disease is not unknown. Few studies have addressed the cause of death in this population. METHODS:Retrospective review of clinicopathologic ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26717

    authors: Upadhyaya SA,Ghazwani Y,Wu S,Broniscer A,Boop FA,Gajjar A,Qaddoumi I

    更新日期:2018-01-01 00:00:00

  • Predictors for neonatal thrombocytopenia in infants of thrombocytopenic mothers during pregnancy.

    abstract:BACKGROUND:Although maternal thrombocytopenia during pregnancy is common, its effect on neonatal platelets has not yet been fully evaluated. METHODS:We retrospectively evaluated the rate of thrombocytopenia among 767 healthy term neonates (gestational age 37-42 weeks) born to 723 mothers with pregnancy-induced thrombo...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22514

    authors: Maayan-Metzger A,Leibovitch L,Schushan-Eisen I,Strauss T,Kenet G,Kuint J

    更新日期:2010-07-15 00:00:00

  • The relationship between ventricular volume and whole-brain irradiation dose in central nervous system germ cell tumors.

    abstract:BACKGROUND:Advanced irradiation techniques, including intensity-modulated radiation therapy (IMRT), aim to limit irradiation to adjoining tissues by conforming beams to a well-defined volume. In intracranial germinomas, whole-ventricular IMRT decreases the volume of irradiation to surrounding parenchyma. This study exa...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28005

    authors: Toll SA,Jones MT,Yoshida EJ,Dhall G,Olch AJ,Wong KK

    更新日期:2019-12-01 00:00:00

  • Assessment of Financial Burden as a Standard of Care in Pediatric Oncology.

    abstract::Family financial hardship has emerged as a burden of pediatric cancer treatment with negative implications for family well-being. As part of an extensive project to create evidence-based standards for the psychosocial care of children with cancer, we performed a literature review of pediatric cancer-associated financi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.25714

    authors: Pelletier W,Bona K

    更新日期:2015-12-01 00:00:00

  • Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors.

    abstract:BACKGROUND:Wilms tumor is the most common pediatric renal malignancy, but the parameters that are important to its invasion capacity are poorly understood. The aim of this study was to identify new proteins associated with the invasion capacity of Wilms tumor. PROCEDURE:Gene expression profiles for 15 primary Wilms tu...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23003

    authors: Chetcuti A,Aktas S,Mackie N,Ulger C,Toruner G,Alkan M,Catchpoole D

    更新日期:2011-12-01 00:00:00

  • Presentation of acute promyelocytic leukemia as granulocytic sarcoma.

    abstract::Granulocytic sarcoma (GS) is a localized tumor composed of immature myeloid cells. This extramedullary tumor can present before, concurrent with or after the diagnosis of acute myeloid leukemia. GS is extremely uncommon in acute promyelocytic leukemia (APL). As a proportion of patients never develop systemic disease, ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21190

    authors: Worch J,Ritter J,Frühwald MC

    更新日期:2008-03-01 00:00:00

  • PARP1 expression in pediatric central nervous system tumors.

    abstract:BACKGROUND:Despite advances in therapy, outcome in many high-grade pediatric central nervous system (CNS) tumors remains poor. The focus of neuro-oncology research has thus turned towards identifying novel therapeutic targets. Poly(ADP-ribose) polymerase-1 (PARP1) is a DNA repair protein that has been studied in a vari...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22141

    authors: Barton VN,Donson AM,Kleinschmidt-DeMasters BK,Gore L,Liu AK,Foreman NK

    更新日期:2009-12-15 00:00:00

  • A survey of clinical productivity and current procedural terminology (CPT) coding patterns of pediatric hematologist/oncologists.

    abstract:BACKGROUND:Subspecialty-specific normative values for clinical productivity of practicing pediatric hematologist/oncologists have not been well established. This information could be a useful adjunct in administrative decision-making in areas such as necessary levels of physician staffing and development of compensatio...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20068

    authors: Griffin TC,Hutter JJ,Johnson KK,Moscow JA

    更新日期:2004-08-01 00:00:00

  • Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents.

    abstract:OBJECTIVE:The objective of this single-center observational study was to determine the clinical and hematologic responses to intravenous ferric carboxymaltose (FCM) in a cohort of pediatric patients with poor response to oral iron therapy. The occurrence of adverse events was systematically recorded for up to 96 hours ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28614

    authors: Ozsahin H,Schaeppi M,Bernimoulin M,Allard M,Guidard C,van den Ouweland F

    更新日期:2020-10-01 00:00:00

  • Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

    abstract::Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Chil...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.28702

    authors: Verbruggen LC,Wang Y,Armenian SH,Ehrhardt MJ,van der Pal HJH,van Dalen EC,van As JW,Bardi E,Baust K,Berger C,Castagnola E,Devine KA,Gebauer J,Marchak JG,Glaser AW,Groll AH,Haeusler GM,den Hartogh J,Haupt R,Hjorth L

    更新日期:2020-12-01 00:00:00

  • A novel SAMD9 variant identified in patient with MIRAGE syndrome: Further defining syndromic phenotype and review of previous cases.

    abstract::We present here a case of MIRAGE syndrome due to novel variant (c.2318T>C) in the sterile α motif domain-containing protein 9 (SAMD9) gene. Previous reports have described the clinical phenotype, which includes myelodysplasia, recurrent infections, restriction of growth and development, adrenal insufficiency, genitour...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.27726

    authors: Perisa MP,Rose MJ,Varga E,Kamboj MK,Spencer JD,Bajwa RPS

    更新日期:2019-07-01 00:00:00

  • Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.

    abstract:BACKGROUND:Irinotecan is highly active against rhabdomyosarcoma (RMS), yet its tolerability and efficacy in combination with radiation is unknown. We examined local control and toxicities in RMS patients treated with radiotherapy (RT) in combination with radiosensitizing agents irinotecan + carboplatin (I + C). PROCED...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24205

    authors: Dharmarajan KV,Wexler LH,Wolden SL

    更新日期:2013-02-01 00:00:00

  • Improving outcomes for high-risk ALL: translating new discoveries into clinical care.

    abstract::High-risk (HR) acute lymphoblastic leukemia (ALL) remains one of the greatest challenges in pediatric oncology. Relapsed ALL is a leading cause of death in young people, and further improvements in outcome will required the development of therapeutic approaches directed against rational therapeutic targets, as escalat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.22996

    authors: Hunger SP,Raetz EA,Loh ML,Mullighan CG

    更新日期:2011-06-01 00:00:00

  • Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia.

    abstract:BACKGROUND:Deaths during induction chemotherapy for pediatric acute lymphoblastic leukemia (ALL) account for one-tenth of ALL-associated mortality and half of ALL treatment-related mortality. We sought to ascertain patient- and hospital-level factors associated with induction mortality. PROCEDURE:We performed a retros...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24855

    authors: Seif AE,Fisher BT,Li Y,Torp K,Rheam DP,Huang YS,Harris T,Shah A,Hall M,Fieldston ES,Kavcic M,Vujkovic M,Bailey LC,Kersun LS,Reilly AF,Rheingold SR,Walker DM,Aplenc R

    更新日期:2014-05-01 00:00:00

  • Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

    abstract:BACKGROUND:Sorafenib targets multiple pathways thought to be crucial in growth of plexiform neurofibroma (PN) in children with neurofibromatosis type 1 (NF1). Sorafenib has been tolerated with manageable toxicities in adults and children with refractory cancer. We conducted a separate study in this population. Monitori...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24281

    authors: Kim A,Dombi E,Tepas K,Fox E,Martin S,Wolters P,Balis FM,Jayaprakash N,Turkbey B,Muradyan N,Choyke PL,Reddy A,Korf B,Widemann BC

    更新日期:2013-03-01 00:00:00

  • Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.

    abstract:BACKGROUND:Thyroid dysfunction has been reported in up to 52% of patients 1.4 years after treatment with (131) I-Metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), despite the use of potassium-iodide (KI). Our aim was to investigate if the incidence and severity of thyroid damage increases in time. M...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24681

    authors: Clement SC,van Eck-Smit BL,van Trotsenburg AS,Kremer LC,Tytgat GA,van Santen HM

    更新日期:2013-11-01 00:00:00

  • Safety of central venous catheter placement at diagnosis of acute lymphoblastic leukemia in children.

    abstract:BACKGROUND:Central venous catheters (CVC) facilitate the management of patients with cancer. Optimal timing for placement of a CVC is controversial. We sought to determine whether early placement in children with acute lymphoblastic leukemia (ALL), a group at high risk for infection and thrombosis, was associated with ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24010

    authors: Gonzalez G,Davidoff AM,Howard SC,Pui CH,Rao BN,Shenep JL,Wozniak A,Shochat SJ

    更新日期:2012-04-01 00:00:00